Holen Sie sich die Stockscreener-App
64.25
0.53%
-0.34
Vorhandelsmarkt:
64.36
0.11
+0.17%
Schlusskurs vom Vortag:
$64.59
Offen:
$64.48
24-Stunden-Volumen:
644.20K
Relative Volume:
0.55
Marktkapitalisierung:
$5.67B
Einnahmen:
$5.07M
Nettoeinkommen (Verlust:
$-186.75M
KGV:
-27.43
EPS:
-2.3424
Netto-Cashflow:
$-160.43M
1W Leistung:
-4.00%
1M Leistung:
-8.06%
6M Leistung:
+51.39%
1J Leistung:
+149.42%
1-Tages-Spanne:
$63.57
$65.39
1-Wochen-Bereich:
$61.02
$67.53
52-Wochen-Spanne:
$23.65
$75.50
Cg Oncology Inc Stock (CGON) Company Profile
Firmenname
Cg Oncology Inc
Sektor
Branche
Telefon
(949) 409-3700
Adresse
3000 PEGASUS PARK DRIVE, DALLAS
Compare CGON vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
64.25 | 5.70B | 5.07M | -186.75M | -160.43M | -2.3424 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-11 | Eingeleitet | Wedbush | Outperform |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-10-08 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2024-06-28 | Eingeleitet | BofA Securities | Buy |
| 2024-02-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-20 | Eingeleitet | Goldman | Neutral |
| 2024-02-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-14 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cg Oncology Inc Aktie (CGON) Neueste Nachrichten
CGON Stock Chart | CG ONCOLOGY INC (NASDAQ:CGON) - ChartMill
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference - MarketBeat
CGON: Cretostimogene advances toward broad NMIBC use with strong data, scalable manufacturing, and launch prep - TradingView
TimesSquare Capital Management LLC Decreases Stock Holdings in CG Oncology, Inc. $CGON - MarketBeat
Wolfe Research initiates coverage of CG Oncology (CGON) with peer perform recommendation - MSN
CG Oncology stock initiated at Peerperform by Wolfe Research - Investing.com Nigeria
Public immunotherapy drugmaker, Lyda Hill's investment firm grow at Pegasus Park - The Business Journals
CG Oncology Initiated at Peer Perform by Wolfe Research - Moomoo
CGON Initiated Coverage by Wolfe Research -- Rating: Peer Perfor - GuruFocus
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - The Manila Times
Bladder cancer grants back AI biomarker, price transparency research - Stock Titan
CG Oncology stock initiated at Peerperform by Wolfe Research By Investing.com - Investing.com South Africa
Wolfe Research Initiates CG Oncology(CGON.US) With Hold Rating - Moomoo
CGON Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus
CG Oncology, Inc. engages with urology leaders at AUA26 to advance patient care connections - Traders Union
UBS reiterates Buy on CG Oncology stock, cites combo trial data - Investing.com Canada
CG Oncology Price Target Maintained With a $100.00/Share by HC Wainwright & Co. - Moomoo
Wedbush Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $80 - Moomoo
H.C. Wainwright Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Assessing CG Oncology (CGON) Valuation After Strong Phase 2 CORE 008 Cohort CX Trial Data - Sahm
Assessing CG Oncology (CGON) Valuation After Positive Phase 2 CORE-008 Bladder Cancer Data - Yahoo Finance
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $108 - Moomoo
Why CG Oncology Stock Is Sliding Despite Good News - TipRanks
CG Oncology Reports 'Encouraging' Data From Study of Intravesical Combination Therapy to Treat Bladder Cancer - Moomoo
CG Oncology reports positive phase 2 bladder cancer trial data - Investing.com UK
T. Rowe Price (CGON) reports 6.72M shares, 8.0% stake disclosed - Stock Titan
CG Oncology reports positive phase 2 bladder cancer trial data By Investing.com - Investing.com South Africa
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients - The Manila Times
RTW Investments Takes Shared 8.3% Stake in CG Oncology (CGON) - Stock Titan
Bladder cancer trial sees up to 92.3% response with new drug combo - Stock Titan
CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears - MarketBeat
Truist raises CG Oncology stock price target to $82 on NMIBC data - Investing.com
Truist Financial Maintains CG Oncology(CGON.US) With Buy Rating, Raises Target Price to $82 - Moomoo
CG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
CG Oncology stock hits all-time high at 73.61 USD - Investing.com India
CG Oncology stock hits all-time high at 73.61 USD By Investing.com - Investing.com Nigeria
CG Oncology (NASDAQ:CGON) Sets New 12-Month HighStill a Buy? - MarketBeat
BofA Securities Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $83 - Moomoo
Number of shareholders of CG Oncology, Inc. – NASDAQ:CGON - TradingView
Q2 Earnings Estimate for CG Oncology Issued By HC Wainwright - MarketBeat
Bank of America Securities Reaffirms Their Buy Rating on Aktis Oncology, Inc. (AKTS) - The Globe and Mail
CG Oncology jumps as Guggenheim starts at Buy on potential against bladder cancer - MSN
CG Oncology Analysts Boost Their Forecasts Following Q1 Earnings - Sahm
Finanzdaten der Cg Oncology Inc-Aktie (CGON)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):